{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-037280","form_type":"8-K","ticker":"NUVL","cik":"0001861560","company_name":"Nuvalent, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.820499+00:00","generated_at":"2026-06-22T00:02:31.284537+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Nuvalent Q3 net loss $19.7M; NVL-520 shows proof-of-concept; $264.5M offering extends runway into H2 2025","bullets":["Q3 net loss $19.7M ($0.41/sh); cash $240.1M; with $264.5M offering extends runway into H2 2025.","NVL-520 Phase 1 data: no DLTs, activity in heavily pre-treated ROS1+ NSCLC including G2032R and brain metastases.","NVL-655 (ALK inhibitor) enrollment in Phase 1 ALKOVE-1 trial progressing; new preclinical data shows activity against compound mutations.","NVL-330 (HER2 exon 20) preclinical data demonstrates potency, selectivity, brain penetration; potential best-in-class."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-037280","json":"https://secwatch.observer/filing/0001564590-22-037280.json","markdown":"https://secwatch.observer/filing/0001564590-22-037280.md","text":"https://secwatch.observer/filing/0001564590-22-037280.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861560/000156459022037280/0001564590-22-037280-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861560/000156459022037280/nuvl-8k_20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T00:02:31.284537+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}